Abstract: Objectives : To evaluate the diagnostic value of antibodies against a panel of ten tumor-associated anti-gens (TAAs) in the diagnosis of primary hepatocellular carcinoma (HCC) and to develop a valid and reliable di-agnostic method for HCC. Methods : The antibodies against ten TAAs in sera from patients with primary HCCand normal human sera were detected by enzyme-linked immunosorbent assay (ELISA). The validity of test-ing results for each anti-TAA antibody was evaluated by epidemiological methods. Results : When each an-ti-TAA antibody was judged individually the sensitivities were low, but the overall positive rate for HCC washigher than that for normal human sera. With the use of a two-antigen panel, the positive rate was higher thanthat for any individual TAA. The positive rate for the combination of Calnuc and CDK2 was 18.0% and morethan 26.0% for other combinations, with the highest rate of 50.0% found using CyclinE and CIAP, CyclinE andImp1, or CyclinE and Koc. With the successive addition of TAAs to a final total of ten antigens, there was astepwise increase of positive antibody reactions reaching a sensitivity of 88.0% and a specificity of 86.2%.Positive and negative predictive values were 84.6% and 89.3%, respectively, which indicated that parallel as-say of ten TAAs raised the diagnostic rate greatly. Positive likelihood ratio and negative likelihood ratio were6.25 and 0.14, respectively, which showed that the clinical diagnostic value of parallel assay of ten TAAs washigh. Kappa value was 0.74, indicating that the observed value of this assay had a high coincidence with theactual value. Conclusion : This study shows that a panel of ten TAAs can enhance antibody detection for diag-nosis of hepatocellular carcinoma. This approach may be used as a screening tool for populations at high risk for hepatocellular carcinoma and as a routine test in clinical practice.